Cargando…

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastos-Oreiro, Mariana, Gutierrez, Antonio, Reguera, Juan Luís, Iacoboni, Gloria, López-Corral, Lucía, Terol, María José, Ortíz-Maldonado, Valentín, Sanz, Jaime, Guerra-Dominguez, Luisa, Bailen, Rebeca, Mussetti, Alberto, Abrisqueta, Pau, Hernani, Rafael, Luzardo, Hugo, Sancho, Juan-Manuel, Delgado-Serrano, Javier, Salar, Antonio, Grande, Carlos, Bento, Leyre, González de Villambrosía, Sonia, García-Belmonte, Daniel, Sureda, Anna, Pérez-Martínez, Antonio, Barba, Pere, Kwon, Mi, Martín García-Sancho, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336530/
https://www.ncbi.nlm.nih.gov/pubmed/35911769
http://dx.doi.org/10.3389/fimmu.2022.855730
_version_ 1784759558965559296
author Bastos-Oreiro, Mariana
Gutierrez, Antonio
Reguera, Juan Luís
Iacoboni, Gloria
López-Corral, Lucía
Terol, María José
Ortíz-Maldonado, Valentín
Sanz, Jaime
Guerra-Dominguez, Luisa
Bailen, Rebeca
Mussetti, Alberto
Abrisqueta, Pau
Hernani, Rafael
Luzardo, Hugo
Sancho, Juan-Manuel
Delgado-Serrano, Javier
Salar, Antonio
Grande, Carlos
Bento, Leyre
González de Villambrosía, Sonia
García-Belmonte, Daniel
Sureda, Anna
Pérez-Martínez, Antonio
Barba, Pere
Kwon, Mi
Martín García-Sancho, Alejandro
author_facet Bastos-Oreiro, Mariana
Gutierrez, Antonio
Reguera, Juan Luís
Iacoboni, Gloria
López-Corral, Lucía
Terol, María José
Ortíz-Maldonado, Valentín
Sanz, Jaime
Guerra-Dominguez, Luisa
Bailen, Rebeca
Mussetti, Alberto
Abrisqueta, Pau
Hernani, Rafael
Luzardo, Hugo
Sancho, Juan-Manuel
Delgado-Serrano, Javier
Salar, Antonio
Grande, Carlos
Bento, Leyre
González de Villambrosía, Sonia
García-Belmonte, Daniel
Sureda, Anna
Pérez-Martínez, Antonio
Barba, Pere
Kwon, Mi
Martín García-Sancho, Alejandro
author_sort Bastos-Oreiro, Mariana
collection PubMed
description Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4–6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44–0.80); p < 0.001] for PFS, and 0.45 [(95% CI: 0.31–0.64)] for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 versus 2.8 months, respectively, p = 0.027) and OS (58% versus 42% at 12 months, respectively, p = 0.048) than tisa-cel. These differences were maintained in the multivariable analysis. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria.
format Online
Article
Text
id pubmed-9336530
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93365302022-07-30 Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups Bastos-Oreiro, Mariana Gutierrez, Antonio Reguera, Juan Luís Iacoboni, Gloria López-Corral, Lucía Terol, María José Ortíz-Maldonado, Valentín Sanz, Jaime Guerra-Dominguez, Luisa Bailen, Rebeca Mussetti, Alberto Abrisqueta, Pau Hernani, Rafael Luzardo, Hugo Sancho, Juan-Manuel Delgado-Serrano, Javier Salar, Antonio Grande, Carlos Bento, Leyre González de Villambrosía, Sonia García-Belmonte, Daniel Sureda, Anna Pérez-Martínez, Antonio Barba, Pere Kwon, Mi Martín García-Sancho, Alejandro Front Immunol Immunology Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4–6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44–0.80); p < 0.001] for PFS, and 0.45 [(95% CI: 0.31–0.64)] for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 versus 2.8 months, respectively, p = 0.027) and OS (58% versus 42% at 12 months, respectively, p = 0.048) than tisa-cel. These differences were maintained in the multivariable analysis. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. Frontiers Media S.A. 2022-07-12 /pmc/articles/PMC9336530/ /pubmed/35911769 http://dx.doi.org/10.3389/fimmu.2022.855730 Text en Copyright © 2022 Bastos-Oreiro, Gutierrez, Reguera, Iacoboni, López-Corral, Terol, Ortíz-Maldonado, Sanz, Guerra-Dominguez, Bailen, Mussetti, Abrisqueta, Hernani, Luzardo, Sancho, Delgado-Serrano, Salar, Grande, Bento, González de Villambrosía, García-Belmonte, Sureda, Pérez-Martínez, Barba, Kwon and Martín García-Sancho https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bastos-Oreiro, Mariana
Gutierrez, Antonio
Reguera, Juan Luís
Iacoboni, Gloria
López-Corral, Lucía
Terol, María José
Ortíz-Maldonado, Valentín
Sanz, Jaime
Guerra-Dominguez, Luisa
Bailen, Rebeca
Mussetti, Alberto
Abrisqueta, Pau
Hernani, Rafael
Luzardo, Hugo
Sancho, Juan-Manuel
Delgado-Serrano, Javier
Salar, Antonio
Grande, Carlos
Bento, Leyre
González de Villambrosía, Sonia
García-Belmonte, Daniel
Sureda, Anna
Pérez-Martínez, Antonio
Barba, Pere
Kwon, Mi
Martín García-Sancho, Alejandro
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title_full Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title_fullStr Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title_full_unstemmed Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title_short Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
title_sort best treatment option for patients with refractory aggressive b-cell lymphoma in the car-t cell era: real-world evidence from geltamo/geth spanish groups
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336530/
https://www.ncbi.nlm.nih.gov/pubmed/35911769
http://dx.doi.org/10.3389/fimmu.2022.855730
work_keys_str_mv AT bastosoreiromariana besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT gutierrezantonio besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT reguerajuanluis besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT iacobonigloria besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT lopezcorrallucia besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT terolmariajose besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT ortizmaldonadovalentin besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT sanzjaime besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT guerradominguezluisa besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT bailenrebeca besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT mussettialberto besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT abrisquetapau besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT hernanirafael besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT luzardohugo besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT sanchojuanmanuel besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT delgadoserranojavier besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT salarantonio besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT grandecarlos besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT bentoleyre besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT gonzalezdevillambrosiasonia besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT garciabelmontedaniel besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT suredaanna besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT perezmartinezantonio besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT barbapere besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT kwonmi besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups
AT martingarciasanchoalejandro besttreatmentoptionforpatientswithrefractoryaggressivebcelllymphomainthecartcellerarealworldevidencefromgeltamogethspanishgroups